As COVID-19 therapies get emergency-use green lights, the Biden administration must organize a therapeutic review board to help identify what’s working and what’s not.

Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.

White House officials hail convalescent plasma as a major breakthrough, but scientists say evidence supporting its effectiveness is still lacking.

Vaccine experts divided on whether that level of protection is too low or too demanding.

Abbott’s ID NOW test missed the most positive samples among five products given the green light by the FDA to use during the pandemic.